Page last updated: 2024-08-07 15:55:33
Cytochrome P450 2C9
A cytochrome P450 2C9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P11712]
Synonyms
EC 1.14.14.1;
(R)-limonene 6-monooxygenase;
1.14.14.53;
(S)-limonene 6-monooxygenase;
1.14.14.51;
(S)-limonene 7-monooxygenase;
1.14.14.52;
CYPIIC9;
Cholesterol 25-hydroxylase;
Cytochrome P-450MP;
Cytochrome P450 M
Research
Bioassay Publications (290)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.34) | 18.2507 |
| 2000's | 64 (22.07) | 29.6817 |
| 2010's | 180 (62.07) | 24.3611 |
| 2020's | 45 (15.52) | 2.80 |
Compounds (400)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| niacin | Homo sapiens (human) | IC50 | 0.1400 | 1 | 1 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | Homo sapiens (human) | Ki | 0.0037 | 1 | 1 |
| 1-aminobenzotriazole | Homo sapiens (human) | IC50 | 42.9000 | 1 | 1 |
| pleconaril | Homo sapiens (human) | IC50 | 30.0594 | 2 | 2 |
| phenytoin | Homo sapiens (human) | Ki | 8.0000 | 2 | 2 |
| acetaminophen | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| acetazolamide | Homo sapiens (human) | Ki | 0.0190 | 4 | 8 |
| alosetron | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| alprenolol | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| amodiaquine | Homo sapiens (human) | IC50 | 0.9900 | 1 | 1 |
| anastrozole | Homo sapiens (human) | IC50 | 0.0036 | 1 | 1 |
| antipyrine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| benzbromarone | Homo sapiens (human) | IC50 | 1.0895 | 4 | 3 |
| benzbromarone | Homo sapiens (human) | Ki | 0.0190 | 3 | 3 |
| bepridil | Homo sapiens (human) | IC50 | 11.5000 | 1 | 1 |
| 5-methoxypsoralen | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| bisacodyl | Homo sapiens (human) | IC50 | 10.0000 | 1 | 0 |
| bmy 7378 | Homo sapiens (human) | Ki | 0.0013 | 1 | 1 |
| verapamil | Homo sapiens (human) | IC50 | 22.0000 | 1 | 1 |
| candesartan | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| carbamazepine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| celecoxib | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| chlorpromazine | Homo sapiens (human) | IC50 | 24.4000 | 1 | 1 |
| chlorzoxazone | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| cilostazol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 0 |
| cimetidine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| ciprofloxacin | Homo sapiens (human) | IC50 | 43.8628 | 2 | 2 |
| clotrimazole | Homo sapiens (human) | IC50 | 0.0160 | 1 | 0 |
| desipramine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| diclofenac | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| dichlorphenamide | Homo sapiens (human) | Ki | 0.0500 | 1 | 1 |
| diphenhydramine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| econazole | Homo sapiens (human) | IC50 | 0.2000 | 1 | 0 |
| ethoxzolamide | Homo sapiens (human) | Ki | 0.0340 | 1 | 1 |
| felodipine | Homo sapiens (human) | IC50 | 4.5795 | 1 | 0 |
| fexofenadine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| flecainide | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| fluconazole | Homo sapiens (human) | IC50 | 18.7367 | 3 | 3 |
| flufenamic acid | Homo sapiens (human) | Ki | 115,904,000,000.0000 | 1 | 1 |
| fluoxetine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| furosemide | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| liquid crystal polymer | Homo sapiens (human) | IC50 | 5.4433 | 2 | 3 |
| glyburide | Homo sapiens (human) | IC50 | 1.6020 | 1 | 0 |
| haloperidol | Homo sapiens (human) | IC50 | 4.6900 | 1 | 1 |
| miltefosine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| hydrochlorothiazide | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| ibuprofen | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| ibuprofen | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| phenelzine | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| idebenone | Homo sapiens (human) | IC50 | 5.0000 | 1 | 0 |
| imipramine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| ketoprofen | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| khellin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| lansoprazole | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| losartan | Homo sapiens (human) | IC50 | 2.8820 | 1 | 0 |
| mefenamic acid | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| mephenytoin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| methazolamide | Homo sapiens (human) | Ki | 0.0270 | 1 | 1 |
| metoprolol | Homo sapiens (human) | IC50 | 4.8700 | 1 | 1 |
| mexiletine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| miconazole | Homo sapiens (human) | IC50 | 19.1000 | 2 | 1 |
| nevirapine | Homo sapiens (human) | IC50 | 0.1810 | 1 | 1 |
| nicardipine | Homo sapiens (human) | IC50 | 1.6900 | 1 | 1 |
| nicardipine | Homo sapiens (human) | Ki | 0.2800 | 1 | 1 |
| nifedipine | Homo sapiens (human) | IC50 | 3.0600 | 1 | 1 |
| nimodipine | Homo sapiens (human) | IC50 | 2.1900 | 2 | 1 |
| nitrendipine | Homo sapiens (human) | IC50 | 0.3000 | 1 | 0 |
| norfloxacin | Homo sapiens (human) | IC50 | 2.5600 | 1 | 1 |
| omeprazole | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| omeprazole | Homo sapiens (human) | Ki | 45.0000 | 1 | 1 |
| pentamidine | Homo sapiens (human) | IC50 | 75.0000 | 3 | 3 |
| perphenazine | Homo sapiens (human) | IC50 | 10.6000 | 1 | 1 |
| phenacetin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| phenylbutazone | Homo sapiens (human) | Ki | 19.0000 | 1 | 1 |
| probucol | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| propafenone | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| propranolol | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| pyrimethamine | Homo sapiens (human) | Ki | 51.5000 | 1 | 1 |
| raloxifene | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| ranitidine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| riluzole | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| sb 206553 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| vorinostat | Homo sapiens (human) | IC50 | 0.2400 | 1 | 1 |
| sulconazole | Homo sapiens (human) | IC50 | 0.2000 | 1 | 0 |
| sulfaphenazole | Homo sapiens (human) | IC50 | 13.7564 | 31 | 30 |
| sulfaphenazole | Homo sapiens (human) | Ki | 0.3500 | 2 | 2 |
| sulfasalazine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| sulpiride | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| suprofen | Homo sapiens (human) | Ki | 24.3500 | 2 | 2 |
| thiabendazole | Homo sapiens (human) | Ki | 245.0000 | 1 | 1 |
| ticlopidine | Homo sapiens (human) | IC50 | 21.8000 | 1 | 1 |
| tolbutamide | Homo sapiens (human) | IC50 | 0.3920 | 2 | 2 |
| tolbutamide | Homo sapiens (human) | Ki | 70.0000 | 1 | 1 |
| trimethoprim | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| troglitazone | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| tropicamide | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| ici 204,219 | Homo sapiens (human) | IC50 | 2.2575 | 1 | 0 |
| ici 204,219 | Homo sapiens (human) | Ki | 2.5000 | 1 | 1 |
| prednisolone | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| adenosine monophosphate | Homo sapiens (human) | IC50 | 2.6000 | 1 | 1 |
| 1,3-ditolylguanidine | Homo sapiens (human) | Ki | 0.0890 | 1 | 1 |
| phenylhydrazine | Homo sapiens (human) | IC50 | 6.0000 | 1 | 0 |
| naphthazarin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| plumbagin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| podophyllotoxin | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| formestane | Homo sapiens (human) | IC50 | 58.6000 | 1 | 1 |
| megestrol acetate | Homo sapiens (human) | IC50 | 10.0000 | 1 | 0 |
| 2,2-dimethylbutyric acid | Homo sapiens (human) | IC50 | 10,000.0000 | 2 | 2 |
| alpha-naphthoflavone | Homo sapiens (human) | IC50 | 15.0000 | 4 | 4 |
| benzydamine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| erythromycin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| tribromsalan | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| 2-amino-6-methoxybenzothiazole | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| tranylcypromine | Homo sapiens (human) | IC50 | 3.3800 | 2 | 2 |
| stanozolol | Homo sapiens (human) | IC50 | 1.1276 | 1 | 0 |
| danazol | Homo sapiens (human) | IC50 | 0.3000 | 1 | 0 |
| triamcinolone | Homo sapiens (human) | IC50 | 9.4700 | 1 | 1 |
| benzonidazole | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| amoxicillin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| etoposide | Homo sapiens (human) | IC50 | 60.3000 | 1 | 1 |
| ticrynafen | Homo sapiens (human) | Ki | 7.6500 | 2 | 2 |
| diltiazem | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| closantel | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| mifepristone | Homo sapiens (human) | IC50 | 4.9000 | 1 | 1 |
| nitrogenase stabilizing-protective protein, bacteria | Homo sapiens (human) | GI50 | 1.8000 | 1 | 2 |
| finasteride | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| fadrozole | Homo sapiens (human) | IC50 | 0.0000 | 1 | 1 |
| mibefradil | Homo sapiens (human) | IC50 | 2.1400 | 1 | 1 |
| tenidap | Homo sapiens (human) | IC50 | 0.7000 | 1 | 0 |
| duloxetine | Homo sapiens (human) | IC50 | 29.0500 | 2 | 2 |
| mk 0591 | Homo sapiens (human) | IC50 | 0.2502 | 2 | 2 |
| 2-adamantanol | Homo sapiens (human) | IC50 | 22.0000 | 1 | 1 |
| salvin | Homo sapiens (human) | Ki | 9.2000 | 1 | 1 |
| proadifen hydrochloride | Homo sapiens (human) | IC50 | 19.0000 | 1 | 1 |
| telmisartan | Homo sapiens (human) | IC50 | 0.4200 | 1 | 1 |
| isopimpinellin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sertraline | Homo sapiens (human) | IC50 | 14.2500 | 2 | 2 |
| pirlindole | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| voriconazole | Homo sapiens (human) | IC50 | 10.3000 | 2 | 2 |
| bufuralol | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| eperezolid | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| eletriptan | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| 6-paradol | Homo sapiens (human) | IC50 | 10.5000 | 1 | 1 |
| phellopterin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| episesamin | Homo sapiens (human) | Ki | 6.8000 | 1 | 1 |
| 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole | Homo sapiens (human) | IC50 | 0.1617 | 2 | 3 |
| sch 28080 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| marimastat | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mosapride | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| desethylamodiaquine | Homo sapiens (human) | IC50 | 58.0000 | 2 | 2 |
| ramatroban | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| alpha-ergocryptine | Homo sapiens (human) | IC50 | 6.0000 | 1 | 0 |
| omeprazole sulfone | Homo sapiens (human) | Ki | 35.0000 | 1 | 1 |
| chs 828 | Homo sapiens (human) | IC50 | 0.0010 | 1 | 1 |
| tariquidar | Homo sapiens (human) | IC50 | 7.1000 | 1 | 1 |
| 5-hydroxy-3',4',6,7-tetramethoxyflavone | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| pumosetrag | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| naproxen | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| olmesartan | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| anidulafungin | Homo sapiens (human) | IC50 | 17.5000 | 1 | 1 |
| 8-gingerol | Homo sapiens (human) | IC50 | 6.8000 | 1 | 1 |
| 10-gingerol | Homo sapiens (human) | IC50 | 16.3000 | 1 | 1 |
| carbobenzyloxyleucyl-tyrosine chloromethyl ketone | Homo sapiens (human) | IC50 | 14.4000 | 1 | 1 |
| sb 203580 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| memantine hydrochloride | Homo sapiens (human) | IC50 | 1.3761 | 1 | 1 |
| etravirine | Homo sapiens (human) | IC50 | 0.0170 | 1 | 1 |
| troleandomycin | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | Homo sapiens (human) | Ki | 0.0240 | 1 | 1 |
| sr 142806 | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| noscapine | Homo sapiens (human) | IC50 | 8.1773 | 1 | 0 |
| ritonavir | Homo sapiens (human) | IC50 | 2.4580 | 2 | 1 |
| naringenin | Homo sapiens (human) | IC50 | 3.3000 | 1 | 1 |
| quinidine | Homo sapiens (human) | Ki | 32.0000 | 1 | 1 |
| linezolid | Homo sapiens (human) | IC50 | 20.0000 | 2 | 2 |
| gingerol | Homo sapiens (human) | IC50 | 12.1000 | 1 | 1 |
| sb 221284 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| sb 228357 | Homo sapiens (human) | IC50 | 82.0000 | 1 | 1 |
| sb 243213 | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
| dihydroergocristine monomesylate | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| trichostatin a | Homo sapiens (human) | IC50 | 0.0280 | 1 | 1 |
| resveratrol | Homo sapiens (human) | IC50 | 7.0000 | 1 | 0 |
| om99-2 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| posaconazole | Homo sapiens (human) | IC50 | 58.1000 | 2 | 2 |
| abt 492 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bay 57-1293 | Homo sapiens (human) | Ki | 0.1228 | 3 | 7 |
| n-nonyl-1-deoxynojirimycin | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| bms-488043 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| tolfenamic acid | Homo sapiens (human) | Ki | 537,650,000,000.0000 | 1 | 1 |
| dibenzylidene acetone | Homo sapiens (human) | IC50 | 33,682.5000 | 1 | 2 |
| cannabidiol | Homo sapiens (human) | Ki | 5.6000 | 1 | 1 |
| pongamol | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| flunarizine | Homo sapiens (human) | IC50 | 0.9400 | 1 | 1 |
| n-hydroxy-n'-(4-butyl-2-methylphenyl)formamidine | Homo sapiens (human) | IC50 | 2.9350 | 3 | 4 |
| maraviroc | Homo sapiens (human) | IC50 | 14.4000 | 1 | 1 |
| telaprevir | Homo sapiens (human) | Ki | 0.0039 | 1 | 1 |
| vx-745 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| dasatinib | Homo sapiens (human) | IC50 | 50.0000 | 1 | 0 |
| silybin | Homo sapiens (human) | Ki | 5.0000 | 1 | 1 |
| sb 242084 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
| quercetin | Homo sapiens (human) | Ki | 27.0000 | 1 | 1 |
| calcitriol | Homo sapiens (human) | IC50 | 0.0093 | 1 | 1 |
| herbacetin | Homo sapiens (human) | IC50 | 8.7000 | 1 | 1 |
| gossypetin | Homo sapiens (human) | IC50 | 24.0000 | 1 | 1 |
| kaempferol | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| amphotericin b | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| baicalein | Homo sapiens (human) | IC50 | 29.0000 | 1 | 1 |
| chrysin | Homo sapiens (human) | IC50 | 5.2250 | 1 | 1 |
| scutellarein | Homo sapiens (human) | IC50 | 38.2000 | 1 | 1 |
| cyclosporine | Homo sapiens (human) | IC50 | 38.8000 | 1 | 1 |
| naloxone | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| sirolimus | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| geldanamycin | Homo sapiens (human) | IC50 | 0.0740 | 1 | 1 |
| istradefylline | Homo sapiens (human) | IC50 | 13.0000 | 1 | 1 |
| 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide | Homo sapiens (human) | IC50 | 0.1900 | 1 | 1 |
| lacidipine | Homo sapiens (human) | IC50 | 2.0000 | 1 | 0 |
| sb 223412 | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| fluvoxamine | Homo sapiens (human) | Ki | 8.5000 | 1 | 1 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | Homo sapiens (human) | IC50 | 0.4000 | 1 | 0 |
| oxiconazole | Homo sapiens (human) | IC50 | 3.0000 | 1 | 0 |
| dextromethorphan | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bedaquiline | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| 2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone | Homo sapiens (human) | IC50 | 1,400.8900 | 1 | 2 |
| ceftriaxone | Homo sapiens (human) | IC50 | 27.4000 | 1 | 1 |
| aliskiren | Homo sapiens (human) | IC50 | 0.0023 | 1 | 1 |
| bms 806 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | Homo sapiens (human) | Ki | 3.3000 | 1 | 1 |
| mdl 73811 | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| rilpivirine | Homo sapiens (human) | IC50 | 0.2818 | 5 | 5 |
| scy-635 | Homo sapiens (human) | IC50 | 13.4000 | 1 | 1 |
| opc-67683 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| gw 1929 | Homo sapiens (human) | IC50 | 4.0000 | 1 | 0 |
| sb 334867-a | Homo sapiens (human) | Ki | 0.8350 | 1 | 1 |
| ispinesib | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| sk&f-38393 | Homo sapiens (human) | Ki | 0.0730 | 1 | 1 |
| fk 866 | Homo sapiens (human) | IC50 | 0.0010 | 1 | 1 |
| (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | Homo sapiens (human) | IC50 | 0.0340 | 1 | 1 |
| n-(4-methylthiazol-2-yl)-2-(6-phenylpyridazin-3-ylthio)acetamide | Homo sapiens (human) | IC50 | 0.5680 | 1 | 1 |
| nifursol | Homo sapiens (human) | IC50 | 7.0000 | 1 | 0 |
| dov 216303 | Homo sapiens (human) | IC50 | 99.0000 | 1 | 1 |
| orteronel | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| ts-011 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 1 |
| rwj 68354 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 0 |
| gw 803430 | Homo sapiens (human) | IC50 | 10,000.0000 | 1 | 1 |
| l-454,560 | Homo sapiens (human) | IC50 | 0.5200 | 5 | 5 |
| biln 2061 | Homo sapiens (human) | Ki | 0.2000 | 1 | 1 |
| dirlotapide | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| linaprazan | Homo sapiens (human) | IC50 | 22.5000 | 2 | 2 |
| chf 5074 | Homo sapiens (human) | IC50 | 38.0000 | 1 | 1 |
| pimavanserin | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| phenobarbital sodium | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| 4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline | Homo sapiens (human) | Ki | 0.0150 | 1 | 1 |
| way 181187 | Homo sapiens (human) | IC50 | 218.7143 | 2 | 7 |
| 6-(3-hydroxyphenyl)-2-naphthol | Homo sapiens (human) | IC50 | 1.0500 | 1 | 1 |
| ar c155858 | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
| gw 842166x | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| gsk 369796 | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| ccx282-b | Homo sapiens (human) | IC50 | 0.0028 | 1 | 1 |
| ps 540446 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| sb-435495 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| ol-135 | Homo sapiens (human) | IC50 | 0.0052 | 1 | 1 |
| msdc-0160 | Homo sapiens (human) | IC50 | 22.0000 | 1 | 1 |
| bms 599626 | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| mk 0354 | Homo sapiens (human) | IC50 | 1.2000 | 1 | 1 |
| brivanib | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| azd1981 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| dg 041 | Homo sapiens (human) | IC50 | 0.0300 | 1 | 1 |
| bms-626529 | Homo sapiens (human) | IC50 | 32.5000 | 2 | 2 |
| r 1487 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| alogliptin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| oc000459 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd 8931 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gosogliptin | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd2932 | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| ce 224,535 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | Homo sapiens (human) | IC50 | 31.6228 | 1 | 1 |
| apremilast | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mk-0893 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mrk 560 | Homo sapiens (human) | IC50 | 0.3000 | 2 | 2 |
| gw9508 | Homo sapiens (human) | IC50 | 33.0000 | 1 | 1 |
| 5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile | Homo sapiens (human) | IC50 | 50.1187 | 1 | 1 |
| epelsiban | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| jnj 28312141 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mk-0249 | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
| ku-0060648 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| sar 1118 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| dihydrotetrabenazine, (2alpha,3beta,11bbeta)-isomer | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| mgl-3196 | Homo sapiens (human) | IC50 | 22.0000 | 1 | 1 |
| gsk188909 | Homo sapiens (human) | IC50 | 9.0000 | 1 | 1 |
| trelagliptin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| amodiaquine hydrochloride | Homo sapiens (human) | IC50 | 62.0000 | 2 | 2 |
| mf63 compound | Homo sapiens (human) | IC50 | 0.0019 | 1 | 1 |
| tannins | Homo sapiens (human) | IC50 | 4.6074 | 1 | 0 |
| cct129202 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vx-770 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| pamapimod | Homo sapiens (human) | IC50 | 29.0000 | 1 | 1 |
| lumacaftor | Homo sapiens (human) | IC50 | 32.0000 | 1 | 1 |
| ro5126766 | Homo sapiens (human) | IC50 | 0.1600 | 1 | 1 |
| bms 687453 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| gsk 1004723 | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| cct 128930 | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| lu aa33810 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| fevipiprant | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| a 867744 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| azd3988 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd1283 | Homo sapiens (human) | IC50 | 1.6625 | 2 | 2 |
| gsk1482160 | Homo sapiens (human) | IC50 | 0.1000 | 1 | 1 |
| serlopitant | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| montelukast sodium | Homo sapiens (human) | Ki | 7.4000 | 1 | 1 |
| pf 04457845 | Homo sapiens (human) | IC50 | 0.0018 | 1 | 1 |
| gdc 0449 | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| bms 754807 | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
| pci 32765 | Homo sapiens (human) | IC50 | 6.0643 | 3 | 3 |
| N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide | Homo sapiens (human) | IC50 | 4.1905 | 2 | 2 |
| at13148 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 0 |
| pf 3246799 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| cobicistat | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| bms-790052 | Homo sapiens (human) | IC50 | 59.5000 | 3 | 3 |
| pf 3845 | Homo sapiens (human) | IC50 | 0.0026 | 1 | 1 |
| glasdegib | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| azd7687 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| GDC-0623 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mk 2461 | Homo sapiens (human) | IC50 | 1.2000 | 1 | 1 |
| osilodrostat | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| tak-441 | Homo sapiens (human) | IC50 | 0.0044 | 1 | 1 |
| e-52862 | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
| pki 587 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bi 653048 bs h3po4 | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
| bms 694153 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| mk-8033 | Homo sapiens (human) | IC50 | 14.7300 | 1 | 1 |
| mk-7246 | Homo sapiens (human) | IC50 | 8.2000 | 4 | 4 |
| sofosbuvir | Homo sapiens (human) | IC50 | 60.0000 | 1 | 1 |
| (3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gsk 1070916 | Homo sapiens (human) | IC50 | 0.0760 | 1 | 1 |
| gsk525762a | Homo sapiens (human) | IC50 | 27.8000 | 3 | 3 |
| glpg0634 | Homo sapiens (human) | IC50 | 85.0000 | 2 | 2 |
| kaf156 | Homo sapiens (human) | IC50 | 6.0000 | 2 | 2 |
| (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| gsk1210151a | Homo sapiens (human) | IC50 | 7.4875 | 4 | 4 |
| i-bet726 | Homo sapiens (human) | IC50 | 13.0000 | 1 | 1 |
| ml298 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| lesinurad | Homo sapiens (human) | IC50 | 46.1042 | 4 | 24 |
| raltegravir | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| minocycline | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| dicumarol | Homo sapiens (human) | IC50 | 0.3000 | 1 | 0 |
| dicumarol | Homo sapiens (human) | Ki | 1.2500 | 2 | 2 |
| piroxicam | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| mobiflex | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| warfarin | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
| pf 00868554 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| dolutegravir | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
| urmc-099 | Homo sapiens (human) | IC50 | 21.0000 | 1 | 1 |
| ew-7197 | Homo sapiens (human) | Ki | 0.0063 | 1 | 1 |
| cep-32496 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| cep-28122 | Homo sapiens (human) | IC50 | 0.0019 | 1 | 1 |
| pbtz169 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| gsk2336805 | Homo sapiens (human) | IC50 | 33.0000 | 1 | 1 |
| vu0364572 | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| MK-8353 | Homo sapiens (human) | IC50 | 5.0000 | 2 | 2 |
| cfi-400945 | Homo sapiens (human) | IC50 | 0.9400 | 1 | 1 |
| vx-970 | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| gs-9973 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| trv130 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| gsk2879552 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| gne-618 | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| g007-lk | Homo sapiens (human) | IC50 | 0.0581 | 1 | 1 |
| gne-617 | Homo sapiens (human) | IC50 | 0.0020 | 1 | 1 |
| n-((3-isopropylisoxazol-5-yl)methyl)-4-methoxy-3-((1-methylpiperidin-4-yl)oxy)benzamide | Homo sapiens (human) | IC50 | 30.0000 | 2 | 2 |
| vu0467154 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| onc201 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| vt-1161 | Homo sapiens (human) | IC50 | 99.0000 | 1 | 1 |
| azd3759 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| MLI-2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| PF-06446846 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| 3-chloro-5-(6-(5-fluoropyridin-2-yl)pyrimidin-4-yl)benzonitrile | Homo sapiens (human) | IC50 | 15.8489 | 1 | 1 |
| at 9283 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| acyclovir | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| clozapine | Homo sapiens (human) | IC50 | 14.1000 | 1 | 1 |
| 2-[(4-chlorophenyl)methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one | Homo sapiens (human) | IC50 | 19.0000 | 1 | 1 |
| mk 6892 | Homo sapiens (human) | IC50 | 39.0000 | 1 | 1 |
| xav939 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| bms 536924 | Homo sapiens (human) | IC50 | 1.2000 | 1 | 1 |
| ver 52296 | Homo sapiens (human) | IC50 | 0.0080 | 1 | 1 |
| 4-[[(4-oxo-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-2-yl)thio]methyl]benzoic acid methyl ester | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| XL413 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| amg 221 | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| thiamet g | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| as1940477 | Homo sapiens (human) | IC50 | 19.0000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 20, Issue:11, 2010
GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action.Journal of medicinal chemistry, , 04-13, Volume: 60, Issue:7, 2017
Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.European journal of medicinal chemistry, , Jul-23, Volume: 82, 2014
Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activity.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods.Journal of medicinal chemistry, , Feb-14, Volume: 51, Issue:3, 2008
Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.Bioorganic & medicinal chemistry, , Apr-01, Volume: 16, Issue:7, 2008
Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors.Journal of medicinal chemistry, , Dec-30, Volume: 47, Issue:27, 2004
[no title available],
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 30, Issue:20, 2020
A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity.Bioorganic & medicinal chemistry, , 08-15, Volume: 26, Issue:15, 2018
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 27, Issue:15, 2017
2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.Journal of medicinal chemistry, , 05-26, Volume: 59, Issue:10, 2016
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
[no title available]Journal of medicinal chemistry, , 11-24, Volume: 65, Issue:22, 2022
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.Journal of medicinal chemistry, , Apr-14, Volume: 59, Issue:7, 2016
[no title available],
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.Journal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.Journal of medicinal chemistry, , Dec-10, Volume: 58, Issue:23, 2015
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022
[no title available]Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Structure-Based Discovery of Novel NHJournal of medicinal chemistry, , 06-23, Volume: 65, Issue:12, 2022
[no title available]Journal of medicinal chemistry, , 06-09, Volume: 65, Issue:11, 2022
[no title available]Journal of medicinal chemistry, , 09-08, Volume: 65, Issue:17, 2022
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Identification of C5-NHJournal of medicinal chemistry, , 12-23, Volume: 64, Issue:24, 2021
[no title available]Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.European journal of medicinal chemistry, , Mar-05, Volume: 213, 2021
The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 40, 2021
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.European journal of medicinal chemistry, , Aug-15, Volume: 200, 2020
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.Journal of medicinal chemistry, , 02-14, Volume: 62, Issue:3, 2019
Development of Robust 17(Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019
2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.European journal of medicinal chemistry, , Jul-19, Volume: 117, 2016
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).European journal of medicinal chemistry, , Oct-20, Volume: 103, 2015
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 24, Issue:15, 2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.Journal of medicinal chemistry, , Jan-27, Volume: 54, Issue:2, 2011
Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.Journal of medicinal chemistry, , Apr-14, Volume: 54, Issue:7, 2011
Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.Journal of medicinal chemistry, , Oct-09, Volume: 51, Issue:19, 2008
Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseaseJournal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.Journal of medicinal chemistry, , Dec-25, Volume: 51, Issue:24, 2008
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.Journal of medicinal chemistry, , Oct-25, Volume: 44, Issue:22, 2001
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
[no title available],
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
[no title available]European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
(E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 27, Issue:24, 2017
Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 27, Issue:16, 2017
Quinazoline derivatives as selective CYP1B1 inhibitors.European journal of medicinal chemistry, , Apr-21, Volume: 130, 2017
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 29, Issue:6, 2019
Development of Robust 17(Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 24, Issue:15, 2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.ACS medicinal chemistry letters, , Sep-11, Volume: 5, Issue:9, 2014
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.Bioorganic & medicinal chemistry, , Jan-01, Volume: 19, Issue:1, 2011
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Incorporation of a chiral gem-disubstituted nitrogen heterocycle yields an oxazolidinone antibiotic with reduced mitochondrial toxicity.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 29, Issue:18, 2019
Potent oxazolidinone antibacterials with heteroaromatic C-ring substructure.ACS medicinal chemistry letters, , Nov-14, Volume: 4, Issue:11, 2013
Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit.European journal of medicinal chemistry, , Volume: 63, 2013
Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
[no title available]European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor.Bioorganic & medicinal chemistry letters, , Dec-03, Volume: 11, Issue:23, 2001
Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT2C receptor antagonist.Journal of medicinal chemistry, , Oct-24, Volume: 40, Issue:22, 1997
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 23, Issue:21, 2013
Synthesis and biological activity of 2-(3'-hydroxypropylidene)-1α-hydroxy-19-norvitamin D analogues with shortened alkyl side chains.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
[no title available]European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
[no title available]Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.Journal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
[no title available]Journal of medicinal chemistry, , 05-14, Volume: 63, Issue:9, 2020
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 20, Issue:22, 2010
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 19, Issue:17, 2009
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 18, Issue:20, 2008
Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 18, Issue:4, 2008
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
Orally active C-6 heteroaryl- and heterocyclyl-substituted imidazo[1,2-a]pyridine acid pump antagonists (APAs).Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 19, Issue:13, 2009
Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs).Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 19, Issue:23, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epiderJournal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dysJournal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).Journal of medicinal chemistry, , Mar-11, Volume: 53, Issue:5, 2010
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).Bioorganic & medicinal chemistry, , 01-15, Volume: 28, Issue:2, 2020
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 20, Issue:22, 2010
Discovery and Evaluation of Pyrazolo[3,4-ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.Journal of medicinal chemistry, , 09-12, Volume: 62, Issue:17, 2019
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.Bioorganic & medicinal chemistry letters, , 11-15, Volume: 28, Issue:21, 2018
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 28, Issue:17, 2018
p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.Journal of medicinal chemistry, , Oct-22, Volume: 52, Issue:20, 2009
Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 18, Issue:15, 2008
Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).Journal of medicinal chemistry, , Sep-25, Volume: 57, Issue:18, 2014
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 23, Issue:7, 2013
Synthesis and evaluation of novel potent HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 22, Issue:14, 2012
New indole amide derivatives as potent CRTH2 receptor antagonists.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 21, Issue:11, 2011
Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 21, Issue:1, 2011
Azaindoles as potent CRTH2 receptor antagonists.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 21, Issue:2, 2011
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 19, Issue:16, 2009
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.Bioorganic & medicinal chemistry letters, , 04-01, Volume: 30, Issue:7, 2020
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.Journal of medicinal chemistry, , 07-13, Volume: 60, Issue:13, 2017
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.Journal of medicinal chemistry, , Oct-10, Volume: 56, Issue:19, 2013
Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.Journal of medicinal chemistry, , 12-22, Volume: 65, Issue:24, 2022
Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in cJournal of medicinal chemistry, , Dec-13, Volume: 55, Issue:23, 2012
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.Journal of medicinal chemistry, , Feb-12, Volume: 58, Issue:3, 2015
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 22, Issue:8, 2012
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 22, Issue:8, 2012
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.Journal of medicinal chemistry, , Jul-27, Volume: 43, Issue:15, 2000
[no title available],
Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/Journal of medicinal chemistry, , May-22, Volume: 57, Issue:10, 2014
Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.Bioorganic & medicinal chemistry letters, , 10-01, Volume: 26, Issue:19, 2016
Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 25, Issue:8, 2015
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:1, 2013
Characterization of human cytochrome P450s involved in the bioactivation of clozapine.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:3, 2013
Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Enables
This protein enables 14 target(s):
| Target | Category | Definition |
|---|
| monooxygenase activity | molecular function | Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water. [ISBN:0198506732] |
| iron ion binding | molecular function | Binding to an iron (Fe) ion. [GOC:ai] |
| arachidonic acid epoxygenase activity | molecular function | Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to a cis-epoxyeicosatrienoic acid. [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, PMID:18952572] |
| steroid hydroxylase activity | molecular function | Catalysis of the formation of a hydroxyl group on a steroid by incorporation of oxygen from O2. [ISBN:0721662544] |
| arachidonic acid 14,15-epoxygenase activity | molecular function | Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-14,15-epoxyeicosatrienoic acid. [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, RHEA:51472] |
| arachidonic acid 11,12-epoxygenase activity | molecular function | Catalysis of an NADPH- and oxygen-dependent reaction that converts arachidonic acid to cis-11,12-epoxyeicosatrienoic acid. [http://lipidlibrary.aocs.org/Lipids/eic_hete/index.htm, PMID:10681399, RHEA:51480] |
| oxidoreductase activity | molecular function | Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. [GOC:go_curators] |
| (S)-limonene 6-monooxygenase activity | molecular function | Catalysis of the reaction: (-)-limonene + NADPH + H+ + O2 = (-)-trans-carveol + NADP+ + H2O. [EC:1.14.14.51] |
| (S)-limonene 7-monooxygenase activity | molecular function | Catalysis of the reaction: (4S)-limonene + H+ + NADPH + O2 = (4S)-perillyl alcohol + H2O + NADP+. [EC:1.14.14.52, RHEA:23432] |
| caffeine oxidase activity | molecular function | Catalysis of the reaction: caffeine + O2 + 2 H+ + 2 e- = 1,3,7-trimethyluric acid + H2O. [RHEA:47148] |
| (R)-limonene 6-monooxygenase activity | molecular function | Catalysis of the reaction: (4R)-limonene + H+ + NADPH + O2 = (1R,5S)-carveol + H2O + NADP+. [EC:1.14.14.53, RHEA:18957] |
| aromatase activity | molecular function | Catalysis of the reduction of an aliphatic ring to yield an aromatic ring. [GOC:cb] |
| heme binding | molecular function | Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring. [GOC:ai] |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | molecular function | Catalysis of an oxidation-reduction (redox) reaction in which hydrogen or electrons are transferred from reduced flavin or flavoprotein and one other donor, and one atom of oxygen is incorporated into one donor. [GOC:mah] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| endoplasmic reticulum membrane | cellular component | The lipid bilayer surrounding the endoplasmic reticulum. [GOC:mah] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
| intracellular membrane-bounded organelle | cellular component | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. [GOC:go_curators] |
Involved In
This protein is involved in 14 target(s):
| Target | Category | Definition |
|---|
| xenobiotic metabolic process | biological process | The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:cab2, GOC:krc] |
| steroid metabolic process | biological process | The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus. [ISBN:0198547684] |
| cholesterol metabolic process | biological process | The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues. [ISBN:0198506732] |
| estrogen metabolic process | biological process | The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants. [ISBN:0198506732] |
| monoterpenoid metabolic process | biological process | The chemical reactions and pathways involving monoterpenoid compounds, terpenoids having a C10 skeleton. [ISBN:0198547684] |
| epoxygenase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds including epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids. [GOC:mah, PMID:17979511] |
| urea metabolic process | biological process | The chemical reactions and pathways involving urea, the water soluble compound O=C-(NH2)2. [ISBN:0198506732] |
| monocarboxylic acid metabolic process | biological process | The chemical reactions and pathways involving monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-). [GOC:vk] |
| xenobiotic catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a xenobiotic compound, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| long-chain fatty acid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of a long-chain fatty acid. A long-chain fatty acid has an aliphatic tail containing 13 to 22 carbons. [PMID:18390550] |
| amide metabolic process | biological process | The chemical reactions and pathways involving an amide, any derivative of an oxoacid in which an acidic hydroxy group has been replaced by an amino or substituted amino group, as carried out by individual cells. [GOC:curators] |
| icosanoid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of icosanoids, any of a group of C20 polyunsaturated fatty acids. [ISBN:0198506732] |
| oxidative demethylation | biological process | The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate. [GOC:BHF, GOC:mah, GOC:rl] |
| omega-hydroxylase P450 pathway | biological process | The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation. [GOC:mw, PMID:10681399] |